CA3127776A1 - Anticorps diriges contre m(h)dm2/4 et leur utilisation dans le diagnostic et le traitement du cancer - Google Patents

Anticorps diriges contre m(h)dm2/4 et leur utilisation dans le diagnostic et le traitement du cancer Download PDF

Info

Publication number
CA3127776A1
CA3127776A1 CA3127776A CA3127776A CA3127776A1 CA 3127776 A1 CA3127776 A1 CA 3127776A1 CA 3127776 A CA3127776 A CA 3127776A CA 3127776 A CA3127776 A CA 3127776A CA 3127776 A1 CA3127776 A1 CA 3127776A1
Authority
CA
Canada
Prior art keywords
seq
antibody
fragment
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3127776A
Other languages
English (en)
Inventor
Ehsun Sarafraz-Yazdi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nomocan Pharmaceuticals LLC
Original Assignee
Nomocan Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nomocan Pharmaceuticals LLC filed Critical Nomocan Pharmaceuticals LLC
Publication of CA3127776A1 publication Critical patent/CA3127776A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne, entre autres, certains anticorps anti-M(H)DM2/4 (y compris des anticorps chimériques et humanisés) ou des fragments de liaison à l'antigène de ceux-ci, des compositions pharmaceutiques comprenant des anticorps anti-M(H)DM2/4 ou des fragments de liaison à l'antigène de ceux-ci, des conjugués anticorps-médicament comprenant les anticorps anti-M(H)DM2/4 ou des fragments de liaison à l'antigène de ceux-ci liés à un médicament cytotoxique, et l'utilisation de ces anticorps, fragments, compositions et conjugués pour le traitement du cancer et/ou la prévention de métastases. L'invention concerne, à titre d'exemple, certains anticorps (y compris des anticorps chimériques et humanisés) ou des fragments de liaison à l'antigène de ceux-ci qui se lient de manière spécifique à des épitopes accessibles de manière extracellulaire de M(H)DM2/4 et inhibent la croissance tumorale in vivo, des compositions pharmaceutiques comprenant ces anticorps ou fragments, des conjugués anticorps-médicament comprenant ces anticorps ou fragments, et l'utilisation de ces anticorps, fragments, compositions et conjugués pour le traitement du cancer ou la prévention de métastases.
CA3127776A 2019-01-30 2019-01-30 Anticorps diriges contre m(h)dm2/4 et leur utilisation dans le diagnostic et le traitement du cancer Pending CA3127776A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2019/015900 WO2020159504A1 (fr) 2019-01-30 2019-01-30 Anticorps dirigés contre m(h)dm2/4 et leur utilisation dans le diagnostic et le traitement du cancer

Publications (1)

Publication Number Publication Date
CA3127776A1 true CA3127776A1 (fr) 2020-08-06

Family

ID=65409648

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3127776A Pending CA3127776A1 (fr) 2019-01-30 2019-01-30 Anticorps diriges contre m(h)dm2/4 et leur utilisation dans le diagnostic et le traitement du cancer

Country Status (4)

Country Link
EP (1) EP3917968A1 (fr)
AU (1) AU2019427766A1 (fr)
CA (1) CA3127776A1 (fr)
WO (1) WO2020159504A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019023460A1 (fr) 2017-07-27 2019-01-31 Nomocan Pharmaceuticals Llc Anticorps dirigés contre m(h)dm2/4 et leur utilisation dans le diagnostic et le traitement du cancer
WO2020172115A1 (fr) * 2019-02-20 2020-08-27 Oncolyze, Inc. Anticorps anti-hdm2 destiné à être utilisé dans le traitement du cancer
WO2023194656A1 (fr) * 2022-04-08 2023-10-12 Tilt Biotherapeutics Oy Anticorps monoclonaux pd-l1

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
WO1996033735A1 (fr) 1995-04-27 1996-10-31 Abgenix, Inc. Anticorps humains derives d'une xenosouris immunisee
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5411860A (en) * 1992-04-07 1995-05-02 The Johns Hopkins University Amplification of human MDM2 gene in human tumors
DE4345249C2 (de) * 1993-11-19 1997-12-11 Deutsches Krebsforsch hdm-2-Fragmente mit Bindungsregionen für hdm-2-spezifische Antikörper
WO1996034096A1 (fr) 1995-04-28 1996-10-31 Abgenix, Inc. Anticorps humains derives de xeno-souris immunisees
FR2738151B1 (fr) * 1995-09-04 1997-09-26 Rhone Poulenc Rorer Sa Antagonistes de l'activite oncogenique de la proteine mdm2, et leur utilisation dans le traitement des cancers
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
CA2722378C (fr) 1996-12-03 2015-02-03 Amgen Fremont Inc. Anticorps humains qui se lient au tnf.alpha.
BRPI9809391B8 (pt) 1997-04-14 2021-05-25 Amgen Res Munich Gmbh processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
WO2010040051A2 (fr) 2008-10-03 2010-04-08 The Research Foundation Of State University Of New York Un peptide membranaire résident dans des peptides anticancéreux cause la nécrose de cellules tumorales plutôt que l’apoptose des cellules cancéreuses
EP2409712A1 (fr) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anticorps Anti-CD19 doté de fonctions ADCC et CDC et d'un profil de glycosylation amélioré
KR20170066546A (ko) * 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
US9765117B2 (en) 2015-08-24 2017-09-19 Romek Figa Peptides for treating cancer
WO2019023460A1 (fr) * 2017-07-27 2019-01-31 Nomocan Pharmaceuticals Llc Anticorps dirigés contre m(h)dm2/4 et leur utilisation dans le diagnostic et le traitement du cancer

Also Published As

Publication number Publication date
EP3917968A1 (fr) 2021-12-08
WO2020159504A1 (fr) 2020-08-06
AU2019427766A1 (en) 2021-09-16

Similar Documents

Publication Publication Date Title
US11407840B2 (en) Antibodies to M(H)DM2/4 and their use in diagnosing and treating cancer
AU2012341450B2 (en) Anti-human TROP-2 antibody having antitumor activity in vivo
RU2668170C2 (ru) Анти-в7-н3-антитело
US9670287B2 (en) Anti-human TROP-2 antibody having anti-tumor activity in vivo
US8017118B2 (en) Anti-hDlk-1 antibody having an antitumor activity in vivo
EP4005594A1 (fr) Anticorps contre cd98hc
WO2015076425A1 (fr) Nouvel anticorps monoclonal
CA3127776A1 (fr) Anticorps diriges contre m(h)dm2/4 et leur utilisation dans le diagnostic et le traitement du cancer
US20220098328A1 (en) Antibodies to m(h)dm2/4 and their use in diagnosing and treating cancer
KR101856904B1 (ko) Pauf 단백질에 특이적으로 결합하는 항체 및 이의 용도
HK1195335B (en) Anti-b7-h3 antibody

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240130

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - SMALL

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250722

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250722

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250822

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251127

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20251222

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - SMALL

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260120

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260120